RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (South Korea), Paediatric investigation plan (European Union), Promising Innovative Medicine (United Kingdom), Priority Review (United States)

Structure/Sequence

Sequence Code 18457995

Source: *****

Clinical Trials associated with Efgartigimod Alfa

NCT06831058

/ Not yet recruitingPhase 2IIT

A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Immune-mediated Thrombotic thrombocytopenic purpura (iTTP) is a rare, autoimmune disorder characterized by life-threatening episodes of thrombocytopenia, microangiopathic hemolytic anemia and organ damage. Patients have an unpredictable course punctuated by relapses associated with autoantibody-mediated (primarily IgG) depletion of ADAMTS13, a key regulator of coagulation. ADAMTS13 deficiency during remission has been associated with increased risk of relapse, but also, and potentially more devastating, ischemic stroke.
Until recently, it was presumed that rituximab (a monoclonal antibody targeting B cells) improved relapse-free survival in most patients, but this was based on findings from very small studies. Given concern about stroke and relapse risk, preventive immunosuppression with rituximab has also recently come into practice for patients with falling ADAMTS13 activity (ADAMTS13-relapse). It is expected that following efgartigimod therapy, there will be a rise in ADAMTS13 activity to the normal range that will be sustained during the treatment period. Following withdrawal of therapy, it is expected that most participants will experience a fall in ADAMTS13 activity, demonstrating the safety and efficacy in efgartigimod to reliably but temporarily reduce pathogenic antibodies. This would demonstrate the potential efficacy for efgartigimod as a maintenance therapy to safely prevent relapse of iTTP to be further explored in a larger efficacy study.

Start Date01 May 2025

Sponsor / Collaborator

University of Minnesota

NCT06885762

/ Not yet recruitingPhase 2/3IIT

Safety and Efficacy of Efgartigimod in Guillain-Barré Syndrome

The goal of this clinical trial is to evaluating the efficacy and safety of efgartigimod in the treatment of Guillain-Barré Syndrome and exploring the immunological mechanisms of efgartigimod therapy in Guillain-Barré Syndrome. The main questions it aims to answer are:
Will efgartigimod improve the symptoms of participants? What medical problems do participants have when using efgartigimod?
Participants will:
On day 1 and day 5 of the treatment period, drug A was administered intravenously.
Keep a diary of their symptoms

Start Date13 Apr 2025

Sponsor / Collaborator

Xinqiao Hospital

NCT06528392

/ Not yet recruitingPhase 2IIT

Efgartigimod for Stiff Person Syndrome (ESPS)

The goal of this clinical trial is to examine the proportion of patients with stiff person syndrome with no worsening in stiffness and/or spasms while on efgartigimod-hyaluronidase (EFD) when compared to their current treatment. The main questions it aims to answer are:
* proportion of patients with stiff person syndrome with no worsening in DSI and HSS scores
* whether there are changes in laboratory values, vital signs, electrocardiogram, or depression, and suicide risk during the trial, as well as the incidence of any adverse events.
Participants will come to the clinic up to 18 times and have up to 5 phone call visits during the course of the trial. During these visits a variety of measures will be collected, including blood samples, neurological and physical exams, patient reported outcomes on stiffness, spasms, depression, and suicide risk.

Start Date01 Apr 2025

Sponsor / Collaborator

University of South Florida

100 Clinical Results associated with Efgartigimod Alfa

100 Translational Medicine associated with Efgartigimod Alfa

100 Patents (Medical) associated with Efgartigimod Alfa

174

Literatures (Medical) associated with Efgartigimod Alfa

31 Dec 2025·Human Vaccines & Immunotherapeutics

Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models

Article

Author: Vanhoenacker, Peter ; Baumeister, Judith ; Wouters, Heidi ; Schotsaert, Michael ; Laghlali, Gabriel ; Ulrichts, Peter ; Chang, Lauren A ; Singh, Gagandeep ; Binazon, Ornella ; Warang, Prajakta ; Elhemdaoui, Nadia ; Augustynková, Kateřina ; Moshir, Mahan ; Steeland, Sophie ; Notebaert, Margo

Antagonism of the neonatal Fc receptor through an engineered antibody Fc fragment, such as efgartigimod, results in a decrease in immunoglobulin G levels. This approach is being evaluated as a therapeutic strategy for the treatment of IgG-mediated autoimmune diseases. Our goal was to evaluate the impact of mFc-ABDEG, a mouse-adapted antibody Fc fragment with a mode of action highly similar to efgartigimod, on vaccine-induced protective immune responses against viral infections. Therefore, mouse vaccination models for COVID-19 and influenza were employed, utilizing an mRNA COVID-19 vaccine (COMIRNATY) and an adjuvanted, inactivated quadrivalent influenza vaccine (Seqirus+AddaVax), respectively. In both models, vaccination induced robust humoral responses. As expected, animals treated with mFc-ABDEG had lower levels of virus-specific IgG, while virus-specific IgM responses remained unaffected. The COVID-19 vaccine induced a strong Th1-type T cell response irrespective of mFc-ABDEG treatment. Influenza vaccination resulted in a poor T cell induction, regardless of mFc-ABDEG treatment, due to the Th2-biased response that inactivated influenza vaccines typically induce. Importantly, mFc-ABDEG treatment had no effect on protective immunity against live viral challenges in both models. Vaccinated animals treated with mFc-ABDEG were equally protected as the non-treated vaccinated controls. These non-clinical data demonstrate that FcRn antagonism with mFc-ABDEG did not affect the generation of vaccine-induced protective humoral and cellular responses, or protection against viral challenges. These data substantiate the clinical observations that, although IgG titers were reduced, FcRn antagonism with efgartigimod did not impair the ability to generate new specific IgG responses, regardless of the timing of vaccination.

01 Jun 2025·LIFE SCIENCES

Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks

Article

Author: Liu, Junyu ; Xu, Xiaofeng ; Yang, Lu ; Li, Min ; Zhou, Yanxia ; Li, Yi ; Peng, Fuhua ; Jiang, Ying ; Zheng, Dong ; Liu, Jia ; Lin, Yanni ; Chen, Xialing

OBJECTIVES:

The purpose of this study was to evaluate the efficacy of Efgartigimod (EFG) in anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis patients during acute attacks.

METHODS:

A case-control study was designed to compare 26 anti-NMDAR encephalitis patients who were treated with EFG, and 15 patients with intravenous immunoglobulin (IVIG), and 23 patients with immunoadsorption with staphylococcal protein A column (SPA-IA) treatment.

RESULTS:

At baseline, no significant differences in mRS scores were observed among the EFG, IVIG, and SPA-IA groups of anti-NMDAR encephalitis patients. When compared with the IVIG group, patients treated with EFG had significantly decreased serum IgG levels. Compared with the SPA-IA group, EFG-treated patients had lower CSF anti-NMDAR antibody titers at admission (p = 0.039) and higher post-treatment IgG levels (p = 0.002). When compared with the IVIG group, SPA-IA patients had higher CASE scores (p = 0.022) and baseline IgG levels (p = 0.023). All groups improved the symptoms of anti-NMDAR encephalitis patients after treatment during acute attacks, with significant decreases in mRS and CASE scores from admission to discharge (p < 0.01). In the EFG and SPA-IA groups, there was a significant reduction in anti-NMDAR antibody titers in both CSF and serum (p < 0.01), while no remarkable decrease was found in the IVIG group. Additionally, serum IgG levels significantly decreased in both the EFG and SPA-IA groups post treatment and during the 1-month follow-up. By the 3-month of follow-up, IgG levels in the blood of both groups remained below the baseline levels.

CONCLUSION:

EFG could be an elegant alternative to both IVIG and SPA-IA therapies for anti-NMDAR encephalitis during acute attacks. It has a better effect on reducing antibody titers than IVIG and is comparable to SPA-IA therapy, and no serious adverse events were observed during infusion.

01 Jun 2025·IMMUNOLOGY LETTERS

Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases

Article

Author: Li, Wei ; Zhang, Jiewen ; Yuan, Lipin ; Liu, Huiqin ; Qin, Jin ; Pang, Rui

OBJECTIVE:

Myasthenia gravis (MG) is an autoimmune disease characterized by disrupted neuromuscular synaptic transmission. Efgartigimod, a human Fc receptor antagonist, has been approved for patients with MG. Its potential use for other IgG-mediated neurological autoimmune diseases is unclear. This study aimed to retrospectively evaluate the efficacy and safety of efgartigimod in patients with neurological autoimmune diseases.

METHODS:

This retrospective study investigated patients with neurological autoimmune diseases who were treated with efgartigimod in the Henan Provincial People's Hospital. The efficacy of the medication was analyzed using the quality-of-life improvement score and the IgG level pre- and post-efgartigimod treatment. The safety of the medication was assessed by considering adverse events and blood parameters. The blood parameters, including routine blood parameters, coagulation, liver, kidney, and immune function.

RESULTS:

Seventeen patients received efgartigimod in the Henan Provincial People's Hospital from September 1, 2023, to January 31, 2024. In MG patients, myasthenia gravis activities of daily living (MG-ADL) reduced after efgartigimod treatment for 4 weeks compared with baseline (P < 0.05). Autoimmune encephalitis (AE) is a group of inflammatory disease with antibodies against neuronal synaptic and cell surface antigens. Similarly, patients with AE had a statistically significant reduction in modified Rankin scale (mRS) after efgartigimod treatment for 4 weeks compared with baseline (P < 0.05). Guillain Barre syndrome (GBS) is an immune-mediated disease of the peripheral nerves and nerve roots. However, the inflammatory neuropathy cause and treatment (INCAT) scale score didn't statistically differ in GBS patients before and after efgartigimod treatment (P > 0.05). The IgG levels significantly reduced after the first infusion and gradually decreased after multiple infusions (P < 0.05). Most subjects did not have increased IgG serum levels before treatment. IgA, IgM, and complement levels didn't differ significantly with efgartigimod treatment (P > 0.05). There were no changes in blood parameters during the treatment (P > 0.05).

CONCLUSIONS:

Efgartigimod was effective and safe in neurological IgG-mediated autoimmune diseases, even in patients without increased IgG serum levels.

298

News (Medical) associated with Efgartigimod Alfa

30 Apr 2025

·endpts.com

FDA approves J&J's rare disease drug that's expected to compete with argenx and UCB

The FDA approved a new rare disease drug that Johnson & Johnson hopes can compete with established medicines — and some that are yet to be approved — and become a megablockbuster. Regulators on Wednesday gave the thumbs-up to nipocalimab, which will be branded as Imaavy, for patients 12 and up with generalized myasthenia gravis, an autoimmune disease that causes muscle weakness, particularly in the eyes, face, throat and lungs. J&J did not immediately share information about how the drug will be priced. The approval sets up a showdown with Rystiggo and Zilbrysq — both of which are marketed by UCB — as well as argenx’s Vyvgart. Through its $39 billion acquisition of Alexion in 2020, AstraZeneca also has a pair of approved drugs: Soliris and Ultomiris. The FDA’s decision came on time, with the agency expected to approve or reject Imaavy by Tuesday (though J&J did not disclose the PDUFA date). The timing of new drug approvals is under increased scrutiny in light of the widespread cuts at the FDA under Commissioner Marty Makary and HHS Secretary Robert F. Kennedy Jr. Stealth BioTherapeutics on Tuesday reported a delay in the FDA’s decision for its Barth syndrome drug, and a person familiar with the situation said it wasn’t related to safety, efficacy or manufacturing. Myasthenia gravis is a category in which biopharma companies have invested heavily in recent years, and the market is expected to reach between $3 billion and $7 billion by the early 2030s, according to analyst estimates. J&J acquired Imaavy in its $6.5 billion acquisition of Momenta in 2020. Soliris was the first drug to be approved for myasthenia gravis in 2017, but sales have been rising for UCB’s drugs and Vyvgart, all of which have different mechanisms of action than Soliris and Ultomiris and are viewed as the next generation of therapies. In 2024, Rystiggo had $202 million in sales — up from just $19 million in 2023 when it launched — and Zilbrysq reached $72 million in its first year on the market. Vyvgart, meanwhile, has already proved itself a rare disease blockbuster, tallying nearly $2.2 billion in sales in 2024 across its IV and subcutaneous formulations. In addition to myasthenia gravis, Vyvgart also received approval last year in another disease called CIDP, which is when a patient’s immune cells attack the peripheral nervous system. J&J has high hopes for Imaavy, saying it expects the drug can reach more than $5 billion in peak sales across all potential indications, should it continue to win approvals. But to carve out a piece of the market, J&J will have its work cut out for it. Amgen is testing its rare disease drug Uplizna in myasthenia gravis, with a filing expected before the end of June. Immunovant also has a drug in late-stage development, while Biohaven has a program expected to soon start Phase 1 studies in myasthenia gravis. Cartesian Therapeutics is working on a cell therapy program as well.

Drug ApprovalAcquisitionCell TherapyImmunotherapy

28 Apr 2025

·www.prnewswire.com

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

European Commission (EC) decision on marketing authorization application expected within approximately two months SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. The SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years. "We are delighted that the subcutaneous injection of VYVGART® co-formulated with our ENHANZE drug delivery technology, has been recommended for approval in the European Union. The positive CHMP opinion moves argenx closer to offering patients throughout Europe a groundbreaking new treatment option. We are proud to support argenx achieve their vision of developing innovative, targeted treatments for patients with rare and severe autoimmune diseases," said Dr. Helen Torley, president and chief executive officer of Halozyme. The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. For more information on the CHMP recommendation, and the ADHERE study and its findings, please view argenx's press release issued on April 28, 2025. The EC is expected to make a decision following CHMP recommendation and the decision will apply to all 27 European Union Member States, and also to Iceland, Norway and Liechtenstein. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indication referred to in this press release. Forward-looking statements may also include statements regarding the product development efforts of Halozyme's ENHANZE® partner and the potential approval of an extension of marketing authorization for the subcutaneous formulation referred to in this press release and the timing of such potential approval. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning whether the extension of marketing authorization for the subcutaneous formulation referred to in this press release is delayed or ultimately approved, unexpected results or delays in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-333-7668 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalClinical Result

28 Apr 2025

·endpts.com

European regulators recommend new drugs from Vertex, Amgen and Jazz

Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European regulators for drugs that are already in the US market. The European Medicines Agency’s human medicines committee (CHMP) said on Friday that it recommended the European Commission to give the go-ahead for six new medicines and 10 label expansions. Among the six new medicines was Vertex’s cystic fibrosis oral therapy called Alyftrek, which was approved by the FDA last December for the same indication. Amgen similarly got a CHMP nod for Tepezza in moderate to severe Thyroid Eye Disease. Tepezza was approved by the FDA for that condition in January 2020. Jazz also secured a positive opinion for its bile duct cancer antibody Ziihera, which was approved by the FDA in November last year. On Friday, the committee said it would re-examine its earlier decision to reject Eli Lilly’s Alzheimer’s drug Kisunla. It also recommends PTC Therapeutics’ drug, dubbed Sephience, to be used to treat hyperphenylalaninemia in patients with the metabolic disease phenylketonuria. The other CHMP medicine recommendations are for Italfarmaco’s therapy Duvyzat for Duchenne muscular dystrophy and Purpose Pharma’s Attrogy for ATTR amyloidosis. As for the 10 label expansions, the committee recommended extending two of Bayer’s drugs, including a new dose of Adempas, which is approved for pulmonary arterial hypertension, as well as extending the label for the hemophilia A drug called Jivi for children aged seven and above. Other label recommendations: The regulators also recommended the EC approve nine new biosimilar products, eight of which were biosimilars to Amgen’s denosumab, which is a treatment for rare bone disease.

Drug Approval

100 Deals associated with Efgartigimod Alfa

External Link

KEGG	Wiki	ATC	Drug Bank
-	Efgartigimod Alfa	-	DB15270

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Purpura, Thrombocytopenic, Idiopathic	Japan	argenx SE	26 Mar 2024
Myasthenia Gravis	United States	arGENX BV	17 Dec 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	NDA/BLA	China	Zai Lab (Shanghai) Co., Ltd.	24 Apr 2024
Primary Sjögren's syndrome	Phase 3	United States	argenx SE	04 Dec 2024
Graves Ophthalmopathy	Phase 3	United States	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	China	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Japan	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Austria	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Bulgaria	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	France	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Germany	argenx SE	28 Mar 2024
Graves Ophthalmopathy	Phase 3	Italy	argenx SE	28 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04980495 (ADAPT NXT, Neurology \| AAN2025) Manual	Phase 3	Myasthenia Gravis	69	efgartigimod fixed-cycle(4 once-weekly infusions, 4 weeks between cycles) (Part A)	dgxmvnzchw(obhpgeygpo) = lmmrmhqoml ebvvfaahsq (nazhosjtod, -6.5 to -3.8) View more	Positive	07 Apr 2025
				efgartigimod Q2W (Part A)	dgxmvnzchw(obhpgeygpo) = qynsrbeiih ebvvfaahsq (nazhosjtod, -5.4 to -3.8) View more
ADAPT/ADAPT+ and ADAPT-SC/ADAPT-SC+ (AAN2025)	Not Applicable	Myasthenia Gravis AChR-Ab−	56	Efgartigimod IV	ghnvburwpw(ejlillpjuf) = rpyvjwbtqs kggvrlrtex (nuxufwrwnk ) View more	Positive	07 Apr 2025
NCT04188379 (ADVANCE \| ADVANCE IV, CTgov)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	131	efgartigimod (Efgartigimod)	yxoagmgyqu = zqscxzoycs irzvvnfdkr (qfdkpzmmhf, rxhludxtzq - lhskxjgzlx) View more	-	13 Mar 2025
				Placebo (Placebo)	yxoagmgyqu = nvqgzoibcb irzvvnfdkr (qfdkpzmmhf, lkketeztux - dxqtwcmifp) View more
NCT04687072 (ADVANCE SC, CTgov)	Phase 3	Purpura, Thrombocytopenic, Idiopathic	207	Efgartigimod PH20 SC (Efgartigimod PH20 SC)	pbgvfvkejp = zylzkpjolp tforhdxzul (cuxyopddkj, gudhqdmadq - yygkztarnx) View more	-	31 Oct 2024
				Placebo PH20 SC (Placebo PH20 SC)	pbgvfvkejp = assoxqxtzt tforhdxzul (cuxyopddkj, wcytgimjzw - vbebqhqvmo) View more
NCT04281472 (ADHERE \| ADHERE+, CTgov)	Phase 2	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	322	Efgartigimod PH20 (Stage A: Efgartigimod PH20 SC)	zboghofies = kosxwvhawb khreontynw (arzmobyrzd, wtgoubbjyl - oflznonmwq) View more	-	20 Aug 2024
				Efgartigimod PH20 (Stage B: Efgartigimod PH20 SC)	bbqxorvgll(uymxpnmvll) = fkbqfxczdb nfkpmbdcxf (txbpcxwlfv, awpjkhvsql - rgukeqdyvt) View more
NCT04735432 (ADAPT-SC, NEWS) Manual	Phase 3	Myasthenia Gravis 乙酰胆碱受体（AChR）抗体阳性	-	艾加莫德	rspjxspwwo(blvbxkmnqv) = mxptfuhwku btoiqjewfe (qbnvgfambg ) Met	Non-inferior	17 Jul 2024
				efgartigimod IV	rspjxspwwo(blvbxkmnqv) = yfejbrgprc btoiqjewfe (qbnvgfambg ) Met
EAN2024	Not Applicable	-	-	Efgartigimod IV	wabrwjssao(fszpvtuzsi) = xdagzvxssj sswapfvqzf (cofwsbsrez )	-	28 Jun 2024
				Efgartigimod SC	wabrwjssao(fszpvtuzsi) = oclyzgprmu sswapfvqzf (cofwsbsrez )
EAN2024	Not Applicable	-	-	Efgartigimod IV	mcvzubkuvy(ivxoeknqqj) = hqoklrirxw zrjhqgnikh (jzcibhvqyu, 2.2)	-	28 Jun 2024
EAN2024	Not Applicable	-	-	Efgartigimod	odchibbmfr(kpnfiimzpz) = mhyujfrqzw piwqhtctyb (hxsjydjqbo ) View more	-	28 Jun 2024
P4-14.016 (AAN2024)	Phase 2/3	Autoimmune Diseases IgG-mediated autoimmune disorders	-	Efgartigimod	ghvzlzyqgc(gzlswvqsun) = bhgmgsfkeo qqxbeanmic (luekwbcwpw )	Positive	09 Apr 2024
				Placebo	ghvzlzyqgc(gzlswvqsun) = fdaufmfifl qqxbeanmic (luekwbcwpw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis